Product-related research: how research can contribute to successful life-cycle management.
Declining productivity with decreasing new molecular entity output combined with increased R&D spending is one of the key challenges for the entire pharmaceutical industry. In order to offset decreasing new molecular entity output, life-cycle management activities for established drugs become more and more important to maintain or even expand clinical indication and market opportunities. Life-cycle management covers a whole range of activities from strategic pricing to a next generation product launch. In this communication, we review how research organizations can contribute to successful life-cycle management strategies using phosphodiesterase 5 inhibitors as an example.
Sandner
Peter
P
Bayer HealthCare AG, Global Drug Discovery, Germany. peter.sandner@bayerhealthcare.com
Ziegelbauer
Karl
K
D000818:Animals; D001688:Biological Products; D035843:Biomedical Research; D002626:Chemistry, Pharmaceutical; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry; D006801:Humans; D018973:Intellectual Property; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors
D001688:Biological Products; D004338:Drug Combinations; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors